ThinkEquity Conference – October 30, 2025
October 28, 2025
Robert Arch, PhD (President) at Immunophotonics will be attending the ThinkEquity Conference at the Mandarin Oriental, New York on October 30th. Robert…
Life Sciences Innovation Forum October 1 & 2, 2025
September 29, 2025
Immunophotonics is excited to be part of the Life Sciences Innovation Forum 2025 in Riyadh! Hosted by J.P. Morgan Asset…
Leadership Announcement at Immunophotonics
September 22, 2025
We’re entering an exciting new chapter at Immunophotonics as we announce key leadership transitions. After more than 15 years of…
Honored to Serve as Founder and CEO of Immunophotonics – Energized for What’s Next
September 19, 2025
Over the past 15+ years – it has been my honor to help build Immunophotonics from its earliest vision into…
Professor Wei Chen named Director of Stephenson School of Biomedical Engineering
September 16, 2025
The Immunophotonics Team is proud to extend our heartfelt congratulations to a co-inventor of IP-001, Professor Wei Chen, on his…
CIRSE September 13–17, 2025
September 16, 2025
Members of our leadership team will be attending the CIRSE 2025 Annual Congress, organized by the Cardiovascular and Interventional Radiological…
Immunophotonics Featured in BioSpace’s Spotlight News
August 27, 2025
Unlocking the Power of the Immune System - One Product, Many Possibilities Immunophotonics is featured in BioSpace’s spotlight on biotechs…
Immunophotonics and Swiss Cancer Institute Complete SAKK 66/17 Phase 1b/2a Multicenter Clinical Trial for Treatment of Solid Tumors
August 21, 2025
Immunophotonics announced the completion of the SAKK 66/17 Phase 1b/2a multicenter clinical trial, conducted in collaboration with the Swiss Cancer…
Immunophotonics Completes Treatment of Last Patient in INJECTABL-1 Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors
July 31, 2025
Immunophotonics has reached a major milestone in its clinical development efforts with the completion of treatment for the final patient…
Professor Wei Chen’s publication in Elsevier Cancer Letters an International Journal
July 9, 2025
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma on their recent publication titled “Anti-tumor effects…